세계의 POC 인플루엔자 진단 시장 - 규모, 점유율, 동향 분석 보고서 : 검사 유형별, 인플루엔자 변종별, 기술별, 최종 용도별, 지역별 부문 예측(2025-2033년)

Point-of-Care Influenza Diagnostics Market Summary

The global point-of-care influenza diagnostics market size was estimated at USD 415.56 million in 2024 and is projected to reach USD 709.52 million by 2033, growing at a CAGR of 6.14% from 2025 to 2033. Increasing global prevalence and severity of seasonal & zoonotic influenza outbreaks, growth in adoption of rapid POC tests, technological advancements in the influenza POC tests, and telehealth & home-based testing integration are key drivers of market growth.

For instance, in October 2023, the International Federation of Red Cross and Red Crescent Societies reported around a billion seasonal flu cases annually, including 3-5 million cases of severe illness, causing 290,000 to 650,000 respiratory deaths annually. Furthermore, in June 2024, F. Hoffmann-La Roche (Switzerland) received approval from the U.S. Food and Drug Administration (FDA) (Emergency Use Authorization (EUA)) for its cobas Influenza A/B & RSV nucleic acid test, an Influenza A multiplex real-time polymerase chain reaction (RT-PCR) assay on the cobas liat system. Producing results in just 20 minutes on a compact analyzer suitable for most healthcare settings, the test uses either a single nasopharyngeal or anterior nasal swab sample to confirm or rule out infection with influenza A and B viruses.

The rapid adoption of point-of-care (POC) tests is a significant factor fostering market growth. These rapid tests provide prompt results, often within minutes, allowing for timely diagnosis and treatment decisions for outpatient and urgent care settings. The convenience and ease of use of rapid influenza diagnostic tests (RIDTs) reduce reliance on centralized laboratories, reduce turnaround time, and improve patient outcomes. Furthermore, these tests are becoming more affordable and accessible, allowing their use in various healthcare settings, such as clinics, pharmacies, and emergency rooms. This shift towards decentralized testing is reinforced by ongoing technological advancements that improve the sensitivity and specificity of rapid tests. Therefore, healthcare providers are more likely to use POC testing as part of routine influenza management, driving market growth, particularly in North America and Europe, with growing adoption in Asia-Pacific markets.

Moreover, one revolutionary factor propelling market expansion is the combination of telehealth and home-based influenza testing. FDA-approved home flu test kits, which are frequently used with telehealth platforms that allow virtual consultations and real-time results transmission to healthcare professionals, have made it possible for people to perform quick diagnostics in the convenience of their own homes. For instance, in October 2024, the Healgen Rapid Check Flu A&B Antigen Test was authorized for sale by the US Food and Drug Administration. The test, available without a prescription and intended for people with respiratory symptoms, uses a nasal swab sample to provide COVID-19 and flu results at home in about 15 minutes. The test can identify proteins from influenza A and B (the viruses that cause the flu).

This integration supports public health initiatives by promoting early detection and isolation, which slows the spread of influenza, and improves patient convenience and testing accessibility. The COVID-19 pandemic made home-based diagnostics easier, raising awareness and acceptance of remote healthcare solutions.

Global Point-of-Care Influenza Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point-of-care influenza diagnostics market based on test type, influenza strain, technology, end-use, and region:

• Test Type Outlook (USD Million, 2021 - 2033)
• Rapid Antigen Tests (RIDT)
• Molecular Point-of-Care Tests
• Biosensor-Based Tests
• Others
• Influenza Strain Outlook (USD Million, 2021 - 2033)
• Influenza A
• Influenza B
• Influenza A & B Combined Tests
• Technology Outlook (USD Million, 2021 - 2033)
• Immunoassay-based
• Molecular Diagnostics
• Nanotechnology based Systems
• Others
• End-use Outlook (USD Million, 2021 - 2033)
• Hospitals
• Clinics
• Homecare Settings
• Others
• Regional Outlook (USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Point-of-Care Influenza Diagnostics Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Test Type
    • 1.1.1.2. Influenza Strain Segment
    • 1.1.1.3. Technology Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Influenza Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Point-of-Care Influenza Diagnostics Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Test Type
• 2.3. Influenza Strain Snapshot
• 2.4. Technology Snapshot
• 2.5. End Use Snapshot
• 2.6. Competitive Landscape Snapshot

Chapter 3. Point-of-Care Influenza Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Increasing global prevalence and severity of seasonal and zoonotic influenza outbreaks
  • 3.4.2. Growth in adoption of rapid POC tests
  • 3.4.3. Technological advancements in the influenza POC tests
  • 3.4.4. Telehealth & home-based testing integration
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost of advanced testing equipment
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Point-of-Care Influenza Diagnostics Market: Test Type Estimates & Trend Analysis

• 4.1. Point-of-Care Influenza Diagnostics Market: Test Type Movement Analysis
• 4.2. Point-of-Care Influenza Diagnostics Market by Test Outlook (USD Million)
• 4.3. Rapid Antigen Tests (RIDT)
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Molecular Point-of-Care Tests
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Biosensor-Based Tests
  • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Point-of-Care Influenza Diagnostics Market: Influenza Strain Estimates & Trend Analysis

• 5.1. Point-of-Care Influenza Diagnostics Market: Influenza Strain Movement Analysis
• 5.2. Point-of-Care Influenza Diagnostics Market by Influenza Strain Outlook (USD Million)
• 5.3. Influenza A
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Influenza B
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Influenza A & B Combined Tests
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Point-of-Care Influenza Diagnostics Market: Technology Estimates & Trend Analysis

• 6.1. Point-of-Care Influenza Diagnostics Market: Technology Movement Analysis
• 6.2. Point-of-Care Influenza Diagnostics Market by Technology Outlook (USD Million)
• 6.3. Immunoassay-based
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Molecular Diagnostics
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Nanotechnology based Systems
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Point-of-Care Influenza Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. Point-of-Care Influenza Diagnostics Market: End Use Movement Analysis
• 7.2. Point-of-Care Influenza Diagnostics Market by End Use Outlook (USD Million)
• 7.3. Hospitals
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Clinics
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Homecare Settings
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Point-of-Care Influenza Diagnostics Market: Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America Point-of-Care Influenza Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. Competitive Scenario
  • 8.2.3. Canada
    • 8.2.3.1. Canada Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Competitive Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.4.2. Key Country Dynamics
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Competitive Scenario
  • 8.3.3. Germany
    • 8.3.3.1. Germany Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Competitive Scenario
  • 8.3.4. Spain
    • 8.3.4.1. Spain Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Competitive Scenario
  • 8.3.5. France
    • 8.3.5.1. France Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Competitive Scenario
  • 8.3.6. Italy
    • 8.3.6.1. Italy Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Competitive Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Competitive Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Competitive Scenario
  • 8.3.9. Norway
    • 8.3.9.1. Norway Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia-Pacific Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Competitive Scenario
  • 8.4.3. China
    • 8.4.3.1. China Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Competitive Scenario
  • 8.4.4. India
    • 8.4.4.1. India Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Competitive Scenario
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Competitive Scenario
  • 8.4.6. Thailand
    • 8.4.6.1. Thailand Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Competitive Scenario
  • 8.4.7. Australia
    • 8.4.7.1. Australia Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Competitive Scenario
• 8.5. Latin America
  • 8.5.1. Latin America Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.2.2. Key Country Dynamics
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Competitive Scenario
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.3.2. Key Country Dynamics
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Competitive Scenario
• 8.6. MEA
  • 8.6.1. MEA Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Competitive Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. Competitive Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. New Product Launch
  • 9.2.2. Partnerships
  • 9.2.3. Acquisition
  • 9.2.4. Collaboration
  • 9.2.5. Funding
• 9.3. Key Company Market Share Analysis, 2024
• 9.4. Company Heat Map Analysis
• 9.5. Company Profiles
  • 9.5.1. Abbott
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Becton Dickinson (BD)
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Danaher/Cepheid
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Quidel Corporation, Inc
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Qiagen
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. F. Hoffmann-La Roche Ltd
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Bio-Rad
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. BioMerieux (Biofire/Idaho Technologies)
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Diasorin (Focus Diagnostics)
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Hologic
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. Thermo/Remel
    • 9.5.11.1. Company Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Strategic Initiatives
  • 9.5.12. Fujirebio.
    • 9.5.12.1. Company Overview
    • 9.5.12.2. Financial Performance
    • 9.5.12.3. Product Benchmarking
    • 9.5.12.4. Strategic Initiatives
  • 9.5.13. Visby Medical
    • 9.5.13.1. Company Overview
    • 9.5.13.2. Financial Performance
    • 9.5.13.3. Product Benchmarking
    • 9.5.13.4. Strategic Initiatives
  • 9.5.14. Twist
    • 9.5.14.1. Company Overview
    • 9.5.14.2. Financial Performance
    • 9.5.14.3. Product Benchmarking
    • 9.5.14.4. Strategic Initiatives